Literature DB >> 17499728

Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP.

Markus Mitterhauser1, Stefan Toegel, Wolfgang Wadsak, Rupert R Lanzenberger, Leonhard-Key Mien, Claudia Kuntner, Thomas Wanek, Harald Eidherr, Dagmar E Ettlinger, Helmut Viernstein, Rainer Kluger, Robert Dudczak, Kurt Kletter.   

Abstract

INTRODUCTION: The objectives of this study were to develop a simple preparation method for [68Ga]-EDTMP and to evaluate the applicability of [68Ga]-EDTMP as a potential positron emission tomography (PET) bone imaging agent using pre vivo, ex vivo and in vivo models.
METHODS: [68Ga]-EDTMP was prepared using 68Ga]-gallium chloride eluted from the 68Ge/68Ga generator and commercially available Multibone kits. Binding affinity to bone compartments was evaluated using a recently established pre vivo model. In vivo (microPET) and ex vivo experiments were performed in mice, and the results of which were compared with those obtained with [18F]-fluoride.
RESULTS: [68Ga]-EDTMP was accessible via simple kit preparation and predominantly accumulated in bone tissue in vivo, ex vivo and pre vivo. Binding to mineral bone was irreversible, and low binding was observed in organic bone. In vivo microPET evaluation revealed predominant uptake in bone with renal excretion. Compared with [18F]-fluoride, the uptake was lower and the PET image quality was reduced.
CONCLUSIONS: From the present evaluation, apart from the autonomy for PET centers without an onsite cyclotron, the advantage of [68Ga]-EDTMP over [18F]-fluoride is not apparent and the future clinical prospect of [68Ga]-EDTMP remains speculative.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17499728     DOI: 10.1016/j.nucmedbio.2007.03.002

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  9 in total

1.  Radiolabeled oligonucleotides for antisense imaging.

Authors:  Arun K Iyer; Jiang He
Journal:  Curr Org Synth       Date:  2011-08-01       Impact factor: 1.975

Review 2.  Image-guided nanosystems for targeted delivery in cancer therapy.

Authors:  A K Iyer; J He; M M Amiji
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

3.  Advances in drug design of radiometal-based imaging agents for bone disorders.

Authors:  Kazuma Ogawa; Hideo Saji
Journal:  Int J Mol Imaging       Date:  2011-12-15

Review 4.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

5.  (177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment.

Authors:  Ralf Bergmann; Marian Meckel; Vojtěch Kubíček; Jens Pietzsch; Jörg Steinbach; Petr Hermann; Frank Rösch
Journal:  EJNMMI Res       Date:  2016-01-16       Impact factor: 3.138

6.  Preparation and Biological Study of (68)Ga-DOTA-alendronate.

Authors:  Ashraf Fakhari; Amir R Jalilian; Fariba Johari-Daha; Mehdi Shafiee-Ardestani; Ali Khalaj
Journal:  Asia Ocean J Nucl Med Biol       Date:  2016

7.  Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid.

Authors:  M Meckel; R Bergmann; M Miederer; F Roesch
Journal:  EJNMMI Radiopharm Chem       Date:  2016-09-23

8.  [68Ga]/[188Re] Complexed [CDTMP] Trans-1,2-Cyclohexyldinitrilotetraphosphonic Acid As a Theranostic Agent for Skeletal Metastases.

Authors:  Ambika P Jaswal; Virendra K Meena; Surbhi Prakash; Ankita Pandey; Baljinder Singh; Anil K Mishra; Puja P Hazari
Journal:  Front Med (Lausanne)       Date:  2017-06-09

Review 9.  Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?

Authors:  Nicolas Lepareur
Journal:  Front Med (Lausanne)       Date:  2022-02-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.